Sangamo Therapeutics, Inc
SGMOQ- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001001233
No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Sangamo Therapeutics, Inc as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 188
- −3 vs. Q1 2022
- Shares held
- 89.7M
- +11.1M (+14.1%) vs. Q1 2022
- Total value
- $371.1M
- −$86.0M (−18.8%) vs. Q1 2022
- New holders
- 18
- 74 more added
- Sold out
- 21
- 46 more reduced
4 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SGMOQ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 6 | $29.0K |
| Q1 2026 | 112 | $26.0M |
| Q4 2025 | 105 | $26.2M |
| Q3 2025 | 112 | $42.1M |
| Q2 2025 | 114 | $39.6M |
| Q1 2025 | 122 | $34.5M |
| Q4 2024 | 128 | $62.9M |
| Q3 2024 | 103 | $48.6M |
| Q2 2024 | 129 | $31.1M |
| Q1 2024 | 131 | $68.2M |
| Q4 2023 | 130 | $47.2M |
| Q3 2023 | 135 | $61.3M |
| Q2 2023 | 152 | $137.4M |
| Q1 2023 | 180 | $197.6M |
| Q4 2022 | 182 | $326.0M |
| Q3 2022 | 197 | $477.2M |
| Q2 2022 | 188 | $371.1M |
| Q1 2022 | 195 | $459.6M |
| Q4 2021 | 193 | $577.0M |
| Q3 2021 | 193 | $679.3M |
| Q2 2021 | 197 | $912.0M |
| Q1 2021 | 203 | $994.7M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Sangamo Therapeutics, Inc; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bedel Financial Consulting, Inc. | 0 | $0 | 0.00% | −730−100.0% | Sold out |
| Bartlett & Co. Wealth Management LLC | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Bartlett & Co. LLC | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −328−100.0% | Sold out |
| Prospera Financial Services Inc | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −89−100.0% | Sold out |
| Heritage Wealth Management, LLC | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Tradewinds Capital Management, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Aaron Wealth Advisors | 0 | $0 | 0.00% | −3,038−100.0% | Sold out |
| Parametric Portfolio Associates LLC | – | – | – | – | Not filed |
| Golden State Equity Partners | – | – | – | – | Not filed |
| KLK Capital Management LLC | – | – | – | – | Not filed |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |